•  
  •  
  •  
  •  

2025-07-11 01:00:58

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
  • Indobell Insulations Ltd secures export order worth $ 48656
  • Manbro Industries Ltd announces strategic acquisitions to strengthen its Value Added Steel Products, Recycling, and Infrastructure Businesses
  • Senores Pharmaceuticals Ltd to increase stake in Havix Group Inc. D/B/A Aavis Pharmaceuticals
  • Consolidated Construction Consortium Ltd order received in FY 2025-2026, till date

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
  • Lupin receives approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
  • Lupin carves out LupinLife Consumer Healthcare
  • Lupin launches Prucalopride tablets in the United States
  • Lupin receives approval from U.S. FDA for Prucalopride Tablets
  • Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Punita Lal Joins Lupin Board as Additional Director
  • Lupin receives approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg
  • Lupin Ltd recommends dividend of Rs. 12
  • Lupin Ltd posts consolidated PAT of Rs. 772.52 crores in Q4 FY2025
  • Lupin launches Eslicarbazepine Acetate Tablets in the United States
  • Lupin receives approval from U.S. FDA for Tolvaptan Tablets
  • Lupin Diagnostics achieves NABL Accreditation for All Greenfield Labs
  • Lupin receives EIR from US FDA for its Injectable Facility in Nagpur
  • US court passes order against Lupin Ltd in Myrbetriq® patent case
  • Lupin announces the acquisition of Renascience in the United Kingdom
  • Lupin Digital Health introduces comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology
  • Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
  • Lupin awarded EcoVadis Silver Medal for Sustainability Excellence, Ranks among the Top 15% Globally
  • Lupin receives tentative approval from U.S. FDA for Amifampridine Tablets
  • Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States

Latest Post

  • Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
  • Indobell Insulations Ltd secures export order worth $ 48656
  • Manbro Industries Ltd announces strategic acquisitions to strengthen its Value Added Steel Products, Recycling, and Infrastructure Businesses
  • Senores Pharmaceuticals Ltd to increase stake in Havix Group Inc. D/B/A Aavis Pharmaceuticals
  • Consolidated Construction Consortium Ltd order received in FY 2025-2026, till date


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024